Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com
Trevi Therapeutics (NASDAQ:TRVI) is set to meet with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) and plans a Phase 2b trial for refractory chronic cough in H1 2026. The company, which is pre-revenue but has seen significant stock gains and strong financial positioning, is developing Haduvio (oral nalbuphine ER), which has shown a statistically significant reduction in cough frequency. Analysts have issued "Buy" ratings and price targets, indicating potential upside, as the company addresses a significant unmet medical need for chronic cough in IPF and non-IPF interstitial lung disease patients.
How this was made
The 30-second read
Why it matters
FDA engagement indicates progress towards potential approval; positive clinical data supports valuation uplift.
Market read
Significant for biotech investors focusing on respiratory therapies; potential catalyst for stock movement.
What to watch
Potential competition from other therapies, and the possibility of adverse clinical trial results impacting stock performance.
Background
Trevi Therapeutics is developing Haduvio for chronic cough associated with IPF, a condition with limited treatment options.
Ticker impact
High relevance due to recent FDA meeting schedule and positive analyst sentiment.
Moderate to significant upward movement (potential 10-20%) over the next 3-6 months if FDA approval process progresses favorably.
The company has demonstrated strong clinical data and analyst support, with scheduled regulatory discussions that could de-risk development and validate commercial potential.
Market effects
Positive impact on the life sciences and biotech sectors, especially companies involved in respiratory and pulmonary therapies.
Potential uplift in South African and global biotech indices with exposure to biotech stocks.
Moderate; primarily relevant to biotech investors and healthcare sector analysts.
Counterpoint
Regulatory approval remains uncertain; delays or setbacks could lead to significant stock declines.
Key entities
- Biotech CompanyTrevi Therapeutics
Developer of therapies for respiratory and neurological conditions.
- Drug CandidateHaduvio
Oral nalbuphine ER for chronic cough in IPF patients.
